Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RETRACTION: The Role and Molecular Mechanism of Trop2 Induced Epithelial-Mesenchymal Transition Through Mediated β-Catenin in Gastric Cancer. | Cancer Med | 2025 | 39988755 | PubTator, text mining | PubMed |
| Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review. | Transl Breast Cancer Res | 2025 | 39980806 | PubTator, text mining | PubMed |
| STANCE: a unified statistical model to detect cell-type-specific spatially variable genes in spatial transcriptomics. | Nat Commun | 2025 | 39979358 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. | Cancer Treat Rev | 2025 | 39978083 | PubTator, text mining | PubMed |
| Five-Gene Expression Signature Associated With Acquired FOLFIRI Resistance and Survival in Metastatic Colorectal Cancer. | Lab Invest | 2025 | 39954853 | PubTator, text mining | PubMed |
| [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study. | J Nucl Med | 2025 | 39947911 | PubTator, text mining | PubMed |
| Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC). | Cancers (Basel) | 2025 | 39941723 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial. | Ann Oncol | 2025 | 39934055 | PubTator, text mining | PubMed |
| FDA approves TROP2-targeted antibody-drug conjugate for breast cancer. | Nat Rev Drug Discov | 2025 | 39929998 | PubTator, text mining | PubMed |
| A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective. | Int J Biol Macromol | 2025 | 39922351 | PubTator, text mining | PubMed |
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. | Ther Adv Med Oncol | 2025 | 39917260 | PubTator, text mining | PubMed |
| The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. | Clin Cancer Res | 2025 | 39903492 | PubTator, text mining | PubMed |
| Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations. | Surg Pathol Clin | 2025 | 39890303 | PubTator, text mining | PubMed |
| Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone. | Clin Cancer Res | 2025 | 39879384 | PubTator, text mining | PubMed |
| Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. | Eur J Nucl Med Mol Imaging | 2025 | 39878898 | PubTator, text mining | PubMed |
| Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition. | Eur J Med Chem | 2025 | 39874630 | PubTator, text mining | PubMed |
| Targeted therapy in TNBC: Exploring the role of antibody-drug conjugates with a focus on sacituzumab govitecan. | J Oncol Pharm Pract | 2025 | 39871785 | PubTator, text mining | PubMed |
| Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer. | Diagnostics (Basel) | 2025 | 39857116 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in urothelial carcinoma: current status and future. | Curr Opin Urol | 2025 | 39844537 | PubTator, text mining | PubMed |
| Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors. | Clin Cancer Res | 2025 | 39841860 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=32